Vanhaecke J, Droogné W, Van Cleemput J, Van de Werf F
Service de Cardiologie Hôpital Universitaire Gasthuisberg, Leuven, Belgique.
Ann Cardiol Angeiol (Paris). 1997 Oct;46(8):527-9.
This article reviews the information derived from various large-scale multicentre studies, summarizes current concepts concerning the mechanisms of action of beta-blockers in heart failure and recalls their modalities of use in this indication. A beneficial effect of beta-blockers on survival has not yet been formally demonstrated. However, the promising results of preliminary trials and progress in the concepts concerning the mechanism of action of beta-blockers suggest that ongoing studies will eliminate any doubts concerning this favourable effect. The action of beta-blockers in heart failure has not yet been entirely elucidated. The multiple mechanisms proposed are situated at various levels, from the organ itself to the subcellular and molecular level. Recent ideas concerning reverse remodelling of the ventricle, correction of altered genetic expression and protection against apoptosis are interdependent and particularly fascinating. The practical use of beta-blockers in this indication is specific and implementation of this treatment requires compliance with several rules, the most important of which are to start treatment at very low doses and to increase the dosage only very gradually.
本文回顾了来自各种大规模多中心研究的信息,总结了目前关于β受体阻滞剂在心力衰竭中作用机制的概念,并回顾了它们在该适应症中的使用方式。β受体阻滞剂对生存率的有益作用尚未得到正式证实。然而,初步试验的有希望的结果以及关于β受体阻滞剂作用机制概念的进展表明,正在进行的研究将消除对这种有利作用的任何疑虑。β受体阻滞剂在心力衰竭中的作用尚未完全阐明。提出的多种机制处于从器官本身到亚细胞和分子水平的各个层面。关于心室逆向重塑、纠正基因表达改变和防止细胞凋亡的最新观点相互依存,特别引人入胜。β受体阻滞剂在该适应症中的实际应用具有特殊性,实施这种治疗需要遵守几条规则,其中最重要的是从非常低的剂量开始治疗,并且仅非常缓慢地增加剂量。